Liafensine

Liafensine is a triple reuptake inhibitor that was initially developed by Biovail, a Canadian pharmaceutical company. It is a nootropic and antidepressant that is designed to increase the levels of serotonin, norepinephrine, and dopamine in the brain.

History

Liafensine was first developed by Biovail, but the development was later taken over by Brainsway, an Israeli medical technology company. The drug is currently in the preclinical stage of development and has not yet been approved for use by the Food and Drug Administration (FDA) or any other regulatory authority.

Mechanism of Action

Liafensine works by inhibiting the reuptake of serotonin, norepinephrine, and dopamine in the brain. This increases the levels of these neurotransmitters in the brain, which can help to improve mood and cognitive function.

Potential Uses

While liafensine is still in the early stages of development, it has potential uses in the treatment of a variety of conditions, including depression, anxiety disorders, and attention deficit hyperactivity disorder (ADHD). However, more research is needed to determine the safety and efficacy of this drug.

Side Effects

As liafensine is still in the preclinical stage of development, the potential side effects are not yet fully known. However, similar drugs that increase the levels of serotonin, norepinephrine, and dopamine in the brain can cause side effects such as nausea, dry mouth, and insomnia.

See Also

• Triple reuptake inhibitors
• Serotonin-norepinephrine-dopamine reuptake inhibitors
• Nootropics
• Antidepressants

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia